Xeris Biopharma Holdings, Inc. (XERS) Market Cap & Valuation Ratios
Xeris Biopharma Holdings, Inc. (XERS) has a market cap of $1.9B and a price-to-sales ratio of 5.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XERSXeris Biopharma Holdings, Inc.Follow XERS — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| XERS | 1.9 | — | 5.9 | 52.5 | 3.0% | +36% | 11% | 28% |
| SUPN | 2.4 | — | 2.6 | — | 0.8% | +25% | -16% | -15% |
| PBH | 2.3 | 13.4 | 3.8 | 13.0 | 10.4% | -1% | 26% | 6% |
| PRGO | 2.2 | — | 1.2 | — | 5.4% | -4% | -38% | -24% |
| TRLV | 2.0 | — | 1.7 | — | 9.3% | -4% | -24% | -27% |
| BCRX | 2.0 | — | 2.1 | — | 19.1% | +69% | -33% | — |
| ANIP | 1.7 | 15.7 | 2.0 | 8.1 | 10.4% | +31% | 15% | 13% |
| PAHC | 1.6 | 15.9 | 1.5 | 9.1 | 0.6% | +17% | 13% | 14% |
| PCRX | 1.5 | 104.1 | 2.1 | 14.9 | 12.4% | +6% | 3% | 2% |
| ETON | 1.4 | — | 13.5 | 68.6 | 1.0% | +81% | 15% | 42% |
| CRON | 1.2 | 16.9 | 2.4 | 36.9 | 4.0% | +37% | -1% | -0.5% |
| Median of these 10 | 15.9 | 2.1 | 13.9 | 7.3% | +21% | 0.7% | 2% |
; EV/Sales 5.9 vs. 2.1.
Growth vs. price
each dot a company · hover or tap for valuesXERS and SUPN and PRGO and TRLV and BCRX and ETON have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Xeris Biopharma Holdings, Inc. — questions
- What is Xeris Biopharma Holdings, Inc.'s market cap?
- $1.9B.
- What is Xeris Biopharma Holdings, Inc.'s price-to-sales ratio?
- 5.5.
Every figure on this page comes from Xeris Biopharma Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.